Circulating prolactin levels in newly diagnosed prostate cancer patients

Authors

  • Hawar Sabah University of Sulaimani, Department of Chemistry and Biochemistry, Qlyasan New Campus, Kurdistan Region, Iraq. Author
  • Dereen Najat Mohammed University of Sulaimani, Department of Chemistry and Biochemistry, Qlyasan New Campus, Kurdistan Region, Iraq. Author

DOI:

https://doi.org/10.17656/jzs.10903

Keywords:

Prostate cancer, prolactin, poly ethylene glycol 6000, sex hormones

Abstract

Objective: the main aim of this study was to assess the role of prolactin in prostate cancer using modern immunoassay methods. Prolactin assays in the past were subject to pitfalls from hook effect and macroprolactinemia; only few previous studies accounted for these pitfalls, therefore and to obtain accurate results, we thought to measure prolactin with modified modern methods. This study also investigated the association of serum prolactin levels with prostate specific antigen and selected steroid and pituitary hormones in prostate cancer patients.

 

Subjects and Methods: serum was withdrawn from newly pretreated 50 prostate cancer patients and 30 controls. The following parameters were studied using Roche-immunoassay analyzers: prolactin, total (PSA), total testosterone, free testosterone, (SHBG), (DHEA), (E2), progesterone, (FSH), (LH) and albumin; to account for macroprolactinemia, serum samples were pretreated with poly ethylene glycol 6000. SPSS statistical software used to perform students’ t test and Pearson’s correlation for association studies. P value of < 0.05 was considered significant throughout the study.

 

Results: 64% of prostate cancer patients had normal prolactin levels (10.04 ±0.039ng/ml), 22% had raised serum prolactin and had 14% low prolactin levels, the difference in prolactin levels between prostate cancer and control group was not significant. Mean PSA levels were ((234.087 ± 522.695ng/ml) in prostate cancer patients, which was significantly higher in the prostate cancer group when compared to the control group (1.25 ± 1.39ng/ml), P ≤ 0.01. Prolactin was not associated with PSA levels or with any of the sex and pituitary hormones studied.

 

Conclusions: although the majority of prostate cancer patients had normal serum prolactin levels, 22% of the study participants had hyperprolactinemia, patients with higher serum prolactin levels had high Gleason score of 9 or higher and were at stage four, indicating a possible role of higher circulating prolactin at advanced cancer stages.

References

Sethi BK, Chanukya G V, Nagesh VS. Prolactin and cancer: Has the orphan finally found a home? Indian J Endocrinol Metab. 2012;16(Suppl 2):S195. DOI: https://doi.org/10.4103/2230-8210.104038

De Bellis A, Bizzarro A, Pivonello R, Lombardi G B. A. Prolactin and autoimmunity.Pituitary. Bellis A, Bizzarro A, Pivonello R, Lomb G, Bellastella. 2005; DOI: https://doi.org/10.1007/s11102-005-5082-5

Grayhack J, Bunce P, Kearns J SW. Influence of the pituitary on prostatic response to androgen in the rat Bull Johns Hopkins Hosp. 1955;

Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JMP. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer. 2004;91(2):305–11. DOI: https://doi.org/10.1038/sj.bjc.6601947

Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer. 2001;92(3):463–5. DOI: https://doi.org/10.1002/ijc.1191

Yu-Lee L-Y. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57:435–56. DOI: https://doi.org/10.1210/rp.57.1.435

Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JSF, et al. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary. 2002;5(4):261–5. DOI: https://doi.org/10.1023/A:1025334001748

Unnikrishnan AG, Rajaratnam S, Seshadri MS, Kanagasapabathy AS, Stephen DC. The ’hook effect’ on serum prolactin estimation in a patient with macroprolactinoma. Neurol India. 2001;49(1):78.

Fahie-Wilson M, Bieglmayer C, Kratzsch J, Nusbaumer C, Roth HJ, Zaninotto M, et al. Roche Elecsys Prolactin II assay: reactivity with macroprolactin compared with eight commercial assays for prolactin and determination of monomeric prolactin by precipitation with polyethylene glycol. Clin Lab. 2007;53(5–6):301–7.

Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, et al. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients? Prostate Cancer Prostatic Dis. 2009;12(1):78–82. DOI: https://doi.org/10.1038/pcan.2008.35

Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72. DOI: https://doi.org/10.1210/jcem.84.10.6079

Eaton NE, Reeves GK, Appleby PN, Key TJ. The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer. Br J Cancer. 1999;80(7):930–4. DOI: https://doi.org/10.1038/sj.bjc.6690445

Lissoni P, Bignami A, Frontini L, Manganini V, Dapretto E, Gardani GS, et al. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer. Int J Biol Markers. 2005;20(2):123–5. DOI: https://doi.org/10.1177/172460080502000207

Costello LC. The suppression of Prolactin is required for the treatment of advanced Prostate cancer. Oncogen. 2019;2(3). DOI: https://doi.org/10.35702/onc.10013

Morales A, Nickel JC. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate. Urology. 1985;26(5):477–81. DOI: https://doi.org/10.1016/0090-4295(85)90158-X

LIu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. European Code against Cancer 4th Edition: Physical activity and cancer☆. Proc Natl Acad Sci. 1995;92(19):8831–5. DOI: https://doi.org/10.1073/pnas.92.19.8831

Ahonen TJ, Häkkönen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology. 1999;140(11):5412–21. DOI: https://doi.org/10.1210/endo.140.11.7090

Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 2004;64(14):4774–82. DOI: https://doi.org/10.1158/0008-5472.CAN-03-3499

Sanati S, Watson MA, Salavaggione AL, Humphrey PA. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol. 2009;22(10):1273–9. DOI: https://doi.org/10.1038/modpathol.2009.103

Roelfsema F, Pijl H, Keenan DM, Veldhuis JD. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One. 2012;7(2):e31305. DOI: https://doi.org/10.1371/journal.pone.0031305

Wu FCW, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, et al. “Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue.,.” J Clin Endocrinol Metab. 2008;93(7):2737–45.

Vijayakumar S, Quadri SF, Dong L, Ignacio L, Kathuria IN, Sutton H, et al. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc. 1995;87(11):813.

Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, et al. High‐grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47(1):52–8. DOI: https://doi.org/10.1002/pros.1046.abs

Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate. 2002;53(3):179–82. DOI: https://doi.org/10.1002/pros.10140

Chen SS, Chen K, Lin ATL, Chang Y, Wu HH, Chang LS. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int. 2002;89(7):710–3. DOI: https://doi.org/10.1046/j.1464-410X.2002.02733.x

Rana A, Habib FK, Halliday P, Ross M, Wild R, Elton RA, et al. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer. 1995;31(6):871–5. DOI: https://doi.org/10.1016/0959-8049(95)00233-2

Isom-Batz G, Bianco Jr FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173(6):1935–7. DOI: https://doi.org/10.1097/01.ju.0000158040.33531.e7

Massengill JC, Sun L, Moul JW, Wu H, McLEOD DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169(5):1670–5. DOI: https://doi.org/10.1097/01.ju.0000062674.43964.d0

Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol. 2015;173(2):D1-12. DOI: https://doi.org/10.1530/EJE-15-0338

Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: A female player in a male game. Nat Rev Urol [Internet]. 2011;8(11):597–607. Available from: http://dx.doi.org/10.1038/nrurol.2011.143 DOI: https://doi.org/10.1038/nrurol.2011.143

Published

2023-06-20

How to Cite

Circulating prolactin levels in newly diagnosed prostate cancer patients. (2023). Journal of Zankoy Sulaimani - Part A, 25(1), 10. https://doi.org/10.17656/jzs.10903

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>